
Jason Porter
@jpmd901
Thoracic Medical Oncologist at West Cancer Center, passionate about screening/early detection, father, singer (my car is my stage), runner, views are my own
ID: 1100479725519208450
https://westcancercenter.org/doctor/jason-porter-md/ 26-02-2019 19:36:27
411 Tweet
695 Followers
853 Following


Honored and thrilled to recruit Erin A Gillaspie, MD, MPH, FACS Vanderbilt University Vanderbilt University Medical Center Vanderbilt Health to join as the Founding Chief of Thoracic Surgery and First Women Chief of Thoracic Surgery Creighton General Surgery Residency Creighton University CreightonSOM CHI Health CommonSpirit Health The Society of Thoracic Surgeons AATS


🙋♂️ INCREDIBLE ICU MOBILITY in intubated patient on ventilator & CRRT 👉This should be the standard of care in all ICU’s and hospitals worldwide 🌎 ❓Does your ICU walk and mobilize intubated patients? H/T Early physiotherapy ICU #ICUrehab #FOAMcc #PhysicalTherapy #MedEd #MedTwitter

Patient advocacy- right ON TARGET! Jill Feldman ##DCLung23





Looking forward to discussing 'Bispecific Inhibitor and ADC in Lung Cancer' at the 20th Miami Cancer Meeting on Jan 20. Excited to share the stage and explore challenging cases with Dr. Luis E. Raez, Edgardo S. Santos, M.D., FACP, FASCO, @DrSteveMartin, Jason Porter! bit.ly/3HpZeaJ



Come join me and Jason Porter this Thursday for the Total Health | Oncology 📖🔬 2024 Diversity Dinner. There will be a lot of great content! #lcsm totalhealthoncology.com/dei



Lovely slide from Marina Garassino . Look at the bottom figures which beautifully document where we are in advanced NSCLC by PDL1 expression levels #ESMO24


#ASTRO24 Dr. Kristin Higgins presents results from NRG LU005: a phase III study of concurrent atezolizumab with chemoradiation followed by 1y of atezo vs CRT and observation for limited stage #SCLC. Note different treatment design, different population than ADRIATIC.


🚨Jazz Pharmaceuticals announces positive results from the phase 3 IMforte study with combination lurbinectedin + atezolizumab in first-line maintenance therapy for ES-SCLC ✅ Statistically significant improvements in OS and PFS vs atezolizumab alone SmallCellSMASHERS OncoAlert #lcsm

Eugene Manley, Jr., Ph.D. and Jason Porter starting the II #lungcancer equity summit Daniel Sumarriva #lcsm

